← Eichor
Study identifier: NCT06124586 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS)

Condition: Diabetic Foot · Diabetes Mellitus · Peripheral Arterial Disease  ·  Sponsor: Heinrich-Heine University, Duesseldorf

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The planned study is a Randomized Controlled Monocentric Trial, which will provide evidence on whether early angiography in percutaneous transluminal angioplasty (PTA) readiness ("immediate" treatment, within 48h) has advantages over the "standard of care", i.e., an elective procedure ("elective PTA") for the treatment of diabetic foot ulcer (DFU). The primary study endpoint is to investigate the impact of the "early PTA" within 48 hours on wound-healing assessed by wound area changes after PTA using a 3D-camera with artificial intelligence (AI)-based wound-analysis-system. The secondary endpoint is the effect of early PTA on the combined occurrence of major adverse limb (MALE) and cardiac events (MACE) over 12 months post-angioplasty using time-to-event analysis. Data will be collected at baseline, 24 hours, 1, 2, 3, 6, and 12 months after PTA. Diabetic kidney disease, distal symmetric polyneuropathy, retinopathy, cardiomyopathy, laboratory analyses, clinical scores, AI-based fundus photography, echocardiography, duplex sonography, and pulse oscillography will be assessed. Explanatory variables for wound healing are wound microbiome changes using whole-genome sequencing and oxygen saturation of the wound environment measured using near-infrared spectroscopy. Altered microbiome composition in ulcers can lead to severe local and systemic infections and complications, including major amputations. Nevertheless, the specific significance of the wound microbiome composition in chr…

This description comes directly from the study's public registry record.

Talk to the study team

Hans Lucas Busch, MD  ·  +49 (0)211 81 08753  ·  hanslucas.busch@med.uni-duesseldorf.de

Lisa Dannenberg, MD  ·  +492118105315  ·  lisa.dannenberg@med.uni-duesseldorf.de

Always discuss trial participation with your own doctor first.

Locations (1)

University-Hospital Düsseldorf Division of Cardiology, Pulmonary Disease and Vascular MedicineDüsseldorf, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06124586